Data from EMA (European Medicines Agency) - Curated by Toby Galbraith - Last updated 20 April 2017

Indication(s)

Adults
Olanzapine is indicated for the treatment of schizophrenia.

Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.

Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure

Hypogonadism

Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more.

Visit Hypogonadism

Related Content

More information

Category Value
Agency product number EMEA/H/C/001087
Orphan designation No
Date First Approved 11-12-2009
Type Medicinal product subject to medical prescription
Marketing authorisation holder Glenmark Pharmaceuticals s.r.o.